A number of firms have modified their ratings and price targets on shares of Exagen (NASDAQ: XGN) recently:
- 11/14/2026 – Exagen was downgraded by Wall Street Zen from “hold” to “sell”.
- 11/11/2026 – Exagen had its price target lowered by Canaccord Genuity Group from $11.00 to $9.00. They now have a “buy” rating on the stock.
- 11/11/2026 – Exagen had its “buy” rating reaffirmed by BTIG Research. They now have a $9.00 price target on the stock.
- 11/4/2026 – Exagen had its “sell (e+)” rating reaffirmed by Weiss Ratings.
- 10/19/2026 – Exagen had its price target raised by Canaccord Genuity Group from $9.00 to $11.00. They now have a “buy” rating on the stock.
- 10/13/2026 – Exagen had its price target raised by TD Cowen from $10.00 to $11.00. They now have a “buy” rating on the stock.
Exagen Trading Down 1.2%
Exagen stock traded down $0.04 during trading on Thursday, hitting $3.85. The company had a trading volume of 373,858 shares, compared to its average volume of 427,123. The company’s 50 day simple moving average is $7.49 and its 200-day simple moving average is $5.13. The company has a current ratio of 3.46, a quick ratio of 3.46 and a debt-to-equity ratio of 1.73. Exagen Inc. has a 1-year low of $2.59 and a 1-year high of $9.22. The stock has a market cap of $98.35 million, a price-to-earnings ratio of -5.14 and a beta of 2.25.
Exagen (NASDAQ:XGN – Get Free Report) last released its quarterly earnings data on Tuesday, November 10th. The company reported ($0.25) EPS for the quarter, missing analysts’ consensus estimates of ($0.18) by ($0.07). Exagen had a negative net margin of 25.14% and a negative return on equity of 125.60%. The business had revenue of $18.42 million during the quarter, compared to analysts’ expectations of $18.34 million. As a group, analysts expect that Exagen Inc. will post -0.74 EPS for the current fiscal year.
Insider Activity at Exagen
In related news, major shareholder Jorey Chernett sold 58,068 shares of the stock in a transaction dated Friday, November 13th. The shares were sold at an average price of $4.08, for a total transaction of $236,917.44. Following the sale, the insider directly owned 2,529,436 shares of the company’s stock, valued at approximately $10,320,098.88. This represents a 2.24% decrease in their position. The sale was disclosed in a document filed with the SEC, which can be accessed through this hyperlink. Also, CEO John Aballi sold 34,294 shares of the firm’s stock in a transaction dated Friday, October 16th. The stock was sold at an average price of $7.87, for a total value of $269,893.78. Following the completion of the transaction, the chief executive officer directly owned 805,540 shares in the company, valued at $6,339,599.80. The trade was a 4.08% decrease in their ownership of the stock. The disclosure for this sale is available in the SEC filing. The sale was made to cover tax withholding obligations related to the vesting of equity awards. In the last quarter, insiders acquired 100,900 shares of company stock valued at $568,660 and sold 213,063 shares valued at $1,084,856. Company insiders own 10.40% of the company’s stock.
Exagen Inc. is a diagnostics company focused on testing for autoimmune and rheumatic diseases. It develops and provides blood tests intended to help physicians assess and monitor conditions such as systemic lupus erythematosus and other connective tissue diseases. The company’s AVISE test portfolio includes diagnostic and monitoring tests that use proprietary biomarkers to support clinical evaluation. Its offerings are designed to provide information that may help clinicians distinguish among autoimmune conditions and guide patient care.
Recommended Stories
- Five stocks we like better than Exagen
- Grand Theft Auto VI Arrives: Why Take-Two Is a Waiting Game
- Greg Abel Makes His Next Moves: Inside Berkshire’s Q3 Portfolio
- Walmart Earnings Change the Narrative as Digital Growth Lifts Outlook
- Whatever Happens to Copper Next, These 3 Investments Offer Different Ways to Play It
Receive News & Ratings for Exagen Inc Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Exagen Inc and related companies with MarketBeat.com's FREE daily email newsletter.
